Hubungan antara Faktor Klinikohistopatologi dan Kualitas Hidup Pasien Kanker Endometrium Pasca Operasi di RSUP Dr.Sardjito Yogyakarta Menggunakan Modul Kuesioner EORTC QLQ-C30 dan EN 24

Dini Mahrani(1*), Ahsanudin Attamimi(2), Ardhanu Kusumanto(3)

(1) Departemen Obstetri dan Ginekologi, FK-KMK,UGM
(2) Departemen Obstetri dan Ginekologi, FK-KMK,UGM
(3) Departemen Obstetri dan Ginekologi, FK-KMK,UGM
(*) Corresponding Author


Background: According to data from the "Endometrial Cancer Report" by the World Cancer Research Fund and the American Institute for Cancer Research (WCRFI), endometrial cancer is the sixth most common malignancy in the world and is the largest cancer in female organs, after cervical cancer. This incidence is increasing every year, it is predicted to increase about 5% of new cases each year. The main prognostic factors of endometrial cancer are determined by the histological type, stage, degree, differentiation of the tumor, invasive myometrial level and increase in lympho-vascular invasion. In addition to determining the histopathological factors, the prognosis is also determined from the clinical patient. Several studies have shown certain clinical factors also improve the condition and prognosis of the disease. Prognosis of this disease with the quality of life of patients becomes an interesting topic to discuss. Besides that quality of life is also a measure of therapeutic success. The better the prognosis of a disease, the better the quality of life, the higher the success rate of therapy (Greimel, 2010).

Objective: To know correlation between clinicohistopathological and quality of life in patients with endometrial cancer after undergoing surgery at Sardjito Hospital, Yogyakarta.

Method: The research is analytic with cross sectional approach. Patients with endometrial cancer who have undergone total hysterectomy and bisalpingoophorectomy surgery are assessed for their quality of life through interviews and filling out questionnaires in the EORTC QLQ-C 30 and QLQ-EN 24 modules.

Results and Discussion: This study, most people with endometrial cancer aged 55-65 years were 34 people (42%) and diagnosed after menopause with a range of age >55 years as many as 43 people (53.1%). This study cannot prove the hypothesis that age, parity, body mass index, type of histopathology and KGB involvement have a relationship with the quality of life of cancer patients (p >0.05). But in contrast to the stage of early cancer (OR 3.17, p=0.044 (CI 95% 1.03-9.75)) and good and moderate differentiation (OR 4.471, p=0.023 (CI 95% 1.23-16.24)) have a significant relationship with quality of life.

Conclusion: Clinicohistopathological factors (cancer stage and tumor differentiation) have a correlation with the quality of life at patients with postoperative endometrial cancer in  Sardjito Hospital 

Keywords: Endometrial cancer; clinicohistopathological factors; quality of life


Endometrial cancer; clinicohistopathological factors; quality of life

Full Text:



  1. Colombo, N., Creutzberg, C., Amant, F., Bosse, T., González-Martín, A., Ledermann, J., Sessa, C. (2016). ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Annals of Oncology, 27(1),16–41.
  2. Evans T, Sany O, Pearmain P, Ganesan R, Blann A, Sundar S. Differential trends in the rising incidence of endometrial cancer by type: data from a UK population-based registry from 1994 to 2006. Br J Cancer. 2011; 104(9): p.1505-1510
  3. Helder-Woolderlink J, De Bock G, Sijmons Rea. The additional value of endometrial sampling in the early detection of endometrial cancer in women with Lynch syndrome. Gynecol Oncol 2013;131(2): p.304-308.
  4. Hoskins WJ, Perez CA, Young RC, Barakat RR, Markman M, Randall ME. Principles and practice of gynecologic oncology, 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 823-63.
  5. Badan Registrasi Kanker IAPI. Data Histopatologi Kanker di Indonesia. Jakarta: Direktorat Jendral Pelayanan Medik Departemen Kesesehatan RI; 2013
  6. Boente MP, Yordan ELJ, McIntosh DG, Grendys ECJ, Orandi YA, Davies S. Prognostic factors and long-term survival in endometrial adenocarcinoma with cervical involvement. Gynecol Oncol 1993;51(3): p.316-322.
  7. Brinton LA, Felix AS, McMeekin DS, Creasman WT, Sherman ME, Mutch D. Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecol Oncol. 2013;129: p.277–84.
  8. Eto T, Saito T, Kasamatsu T, Nakanishi T, Yokota H, Satoh T. Clinicopathological prognostic factors and the role of cytoreduction in surgical stage IVb endometrial cancer: a retrospective multi-institutional analysis of 248 patients in Japan. Gynecol Oncol. 2012;127(2): p.338-344.
  9. Rosenberg P, Risberg B, Askmalm L, Simonsen E. The prognosis in early endometrial carcinoma. The importance of uterine papillary serous carcinoma (UPSC), age, FIGO grade and nuclear grade. Acta Obstet Gynecol Scand. 1989;68(2): p.157-163.
  10. Varughese J, Richman S. Women’ s Health in the Developing World. Cancer Care Inequity for Women in Resource-Poor Countries. 2010;3(1):122–32.
  11. Greimel E, Nordin AJ. Application of quality of life measurements in clinical trials and in clinical practice for gynecologic cancer patients. Expert Rev Pharmacoecon Outcomes Res. 2010.
  12. Kornblith AB, Huang HQ, Walker JL, Spirtos NM, Rotmensch J, Cella D. Quality of life of patients with endometrial cancer undergoing laparoscopic international federation of gynecology and obstetrics staging compared with laparotomy: a Gynecologic Oncology Group. J Clin Oncol. 2010.
  13. World Cancer Research Fund/ American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: Endometrial cancer 2013 report.
  14. National Cancer Institute. Endometrial Cancer. National Institute of Health; 2010.
  15. Hoffman, BL; Schorge, JO; Schaffer, JI; Halvorson, LM; Bradshaw, KD; Cunningham, FG eds. Endometrial Cancer. In: Williams Gynecology (2nd ed). McGraw-Hill. p; 2012. page 819–34.
    1. Ota T, Yoshida M, Kimura M, Kinoshita K. Clinicopathologic study of uterine endometrial carcinoma in young women aged 40 years and younger. Int J Gynecol Cancer. 2005; 15: p.657–662.
    2. Pellerin GP, Finan MA. Endometrial cancer in women 45 years of age or younger : A clinicopathological analysis. Am J Obstet Gynecol 2005; p.1640–4.
    3. Yasumizu T, Ogawa K, Kato J. Comparison of the clinicopathological characteristics of premenopausal and postmenopausal endometrial carcinomas: analysis of endocrinologically evaluated cases. Jpn J Clin Oncol. 1996: p.152-6.
    4. Angioli R., Plotti F., Cafa E.V., Dugo N., Capriglione S., Terranova C. “Quality of life in patients with endometrial cancer treated with or without systematic lymphadenectomy”. Eur. J. Obstet. Gynecol. Reprod. Biol. 2013.
    5. Cella DF. Quality of life outcomes: measurement and validation. Oncology (Williston Park). 1996.
    6. Cocks K, King MT, Velikova G. Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Eur J Cancer. 2012;48(11): p.1713–1721.
    7. Dobrzycka B, Terlikowski R, Kulesza-bronczyk B, Niklinski J. Quality of life in long-term survivors of early stage endometrial cancer. 2017;24(3): p. 513–6.
    8. Aaronson NK, Ahmedzai S, Bergman B. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993.
    9. Fayers PM. AN, Bjordal K., Groenvold M., Curran D., Bottomley A. EORTC QLQ-C30 Scoring Manual. 3rd ed. Brussels: European Organisation for Research and Treatment of Cancer. 2001.
    10. Stukan M, Zalewski K, Mardas M. Independent psychometric validation of European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Endometrial Cancer Module (EORTC QLQ-EN24). Eur J Cancer Care. 2018; p.27.
    11. Iang Yuan, Uan, Heng WZ, Heng JC. Menstrual and reproductive factors and endometrial cancer risk : results from a population-based case-control study in urban shanghai. Int J Cancer. 2004. p: 613–9.
    12. ASTEC/EN.5 Study Group. Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet. 2009.
    13. Benedetti-Panici P, Basile S, Maneschi F, Lissoni AA, Signorelli M, Scambia G. Systematic pelvic lymphadenectomy in early-stage endometrial carcinoma: randomised clinical trial. J Natl Cancer Inst. 2008;100(23): p.1707-1716.
    14. Thomas CC, Wingo PA, Dolan MS, Lee NC, Richardson LC. Endometrial cancer risk among younger, overweight women. Obstet Gynecol. 2009; p.114:22–7.
    15. Lax SF, Kurman RJ, Pizer ES, Wu L, Ronnett BM. A binary architectural grading system for uterine endoemetrial endometrioid carcinoma has superior reproducibility compared with FIGO grading and identifies subsets of advancedstage tumors with favorable and unfavorable prognosis. Am J Surg Pathol 2000; 24: p.1201–1208.
    16. Wright JD, Fiorelli J, Kansler AL, Burke WM, Schiff PB, Cohen CJ. Optimizing the management of stage II endometrial cancer: the role of radical hysterectomy and radiation. Am J Obstet Gynecol. 2009:200(4): p.419.e1-7.
    17. National Institute for Health and Care Excellence. NICE guidelines (NG12) Suspected cancer: recognition and referral. June 2015; Available at:
    18. Johnson N, Cornes P. Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and meta-analysis. Br J Obstet Gynaecol 2007;114: p.1313-1320.


Article Metrics

Abstract views : 2272 | views : 3366


  • There are currently no refbacks.

Copyright (c) 2021 The Author(s)

Creative Commons License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Jurnal Kesehatan Reproduksi Indexed by:



Departemen Obstetri dan Ginekologi, FK-KMK, UGM/RS Dr. Sardjito
Jl. Kesehatan No. 1, Sekip Utara, Yogyakarta 55281
Tlp: (0274) 511329 / Faks: (0274) 544003
Cp: Dwi Astuti +6281802698043